These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 29032713

  • 1. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
    Pollock RF, Muduma G.
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
    [Abstract] [Full Text] [Related]

  • 2. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF, Muduma G.
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [Abstract] [Full Text] [Related]

  • 3. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF, Muduma G.
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [Abstract] [Full Text] [Related]

  • 4. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.
    Pollock RF, Muduma G.
    Clinicoecon Outcomes Res; 2017 Jul; 9():475-483. PubMed ID: 28848355
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
    Delpeuch A, Ruivard M, Abergel A, Aumaitre O, Boisgard S, Bagel S, Sautou V.
    Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
    [Abstract] [Full Text] [Related]

  • 8. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT.
    Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
    [Abstract] [Full Text] [Related]

  • 9. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC, Geisser P.
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL.
    Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group.
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X, Borrás-Blasco J, Molés JR, Boscá M, Cortés E.
    PLoS One; 2015 Sep; 10(5):e0128156. PubMed ID: 26011514
    [Abstract] [Full Text] [Related]

  • 19. Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland.
    Loughnane F, Muduma G, Pollock RF.
    Adv Ther; 2020 Mar; 37(3):1218-1232. PubMed ID: 32030608
    [Abstract] [Full Text] [Related]

  • 20. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
    Bager P, Dahlerup JF.
    J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.